Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 9:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 71 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Perennial Allergic Rhinitis Clear all
Completed Phase 3 Interventional

Safety and Effectiveness of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis During One Year Treatment (BY9010/M1-404)

NCT00163501
View directory record Official record
Conditions
Perennial Allergic Rhinitis, Allergic Rhinitis, Hay Fever
Interventions
Ciclesonide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
41
States / cities
Encinitas, California • Huntington Beach, California • Long Beach, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Sep 16, 2026, 9:10 AM EDT
Completed No phase listed Observational

Evaluation of Safety of Levocetirizine in Routine Clinical Practice-non- Interventional Study

NCT00598780
View directory record Official record
Conditions
Rhinitis Allergic, Persistent
Interventions
Not listed
Lead sponsor
UCB Pharma
Industry
Eligibility
2 Years and older
Enrollment
7,870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Smyrna, Georgia
Source: ClinicalTrials.gov public record
Updated May 27, 2012 · Synced Sep 16, 2026, 9:10 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Children With Perennial Allergic Rhinitis

NCT01018862
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
Azelastine hydrochloride nasal spray 0.15%, Azelastine hydrochloride nasal spray 0.10%, Placebo
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
6 Years to 12 Years
Enrollment
489 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
39
States / cities
Costa Mesa, California • Long Beach, California • Mission Viejo, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2012 · Synced Sep 16, 2026, 9:10 AM EDT
Completed Phase 3 Interventional Results available

A 6 Month Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older

NCT01067105
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
ciclesonide HFA 160 μg
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
824 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
44
States / cities
Huntington Beach, California • Los Angeles, California • Mission Viejo, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2012 · Synced Sep 16, 2026, 9:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nasal Irritation Study: Individual Factors in Nasal Irritant Sensitivity

NCT00041821
View directory record Official record
Conditions
Rhinitis, Allergic, Nonseasonal
Interventions
Nasal irritation thresholds and irritant provocation
Procedure
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years to 69 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2000
U.S. locations
1
States / cities
Richmond, California
Source: ClinicalTrials.gov public record
Updated Mar 22, 2006 · Synced Sep 16, 2026, 9:10 AM EDT
Completed Phase 3 Interventional Results available

Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis

NCT01033825
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
Ciclesonide HFA Nasal Aerosol 320 mcg, Ciclesonide HFA Nasal Aerosol 160 mcg, HFA Nasal Aerosol placebo, Ciclesonide Aqueous Nasal Spray 200 mcg, AQ Nasal Spray Placebo, Placebo plus Dexamethasone HFA, Placebo AQ plus Dexamethasone 6 mg
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
6
States / cities
Stockbridge, Georgia • North Dartmouth, Massachusetts • Minneappolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2012 · Synced Sep 16, 2026, 9:10 AM EDT
Completed Phase 2 Interventional Results available

A Novel Biologic Therapy for Perennial Allergic Rhinitis

NCT03360071
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Allergen Immunotherapy Extract, Allergen Immunotherapy Control
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Sep 16, 2026, 9:10 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of a Novel Questionnaire to Assess Patient Satisfaction With and Preference of Intranasal Corticosteroids for the Treatment of Allergic Rhinitis

NCT01287364
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
ciclesonide hydrofluoroalkane (HFA) nasal aerosol, mometasone nasal inhalation
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
6
States / cities
Mission Viejo, California • San Diego, California • North Dartmouth, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2012 · Synced Sep 16, 2026, 9:10 AM EDT
Completed Phase 4 Interventional Results available

Comparator Study Evaluating Patient Experience And Preference Of FFNS vs. FPNS

NCT00519636
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
FPNS, FFNS, placebo FFNS, placebo FPNS
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2016 · Synced Sep 16, 2026, 9:10 AM EDT
Completed Phase 3 Interventional Results available

Efficacy & Safety of STG320 Sublingual Tablets of HDM Allergen Extracts in Adults and Adolescents With HDM-associated AR

NCT02443805
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial, House Dust Mite Allergy
Interventions
300 IR, Placebo
Biological
Lead sponsor
Stallergenes Greer
Industry
Eligibility
12 Years to 65 Years
Enrollment
1,607 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 13, 2019 · Synced Sep 16, 2026, 9:10 AM EDT
Completed No phase listed Observational

Pilot Study of Allergy Immunotherapy and Prevention of Viral Respiratory Infections

NCT00405899
View directory record Official record
Conditions
Allergy, Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis
Interventions
Not listed
Lead sponsor
West Penn Allegheny Health System
Other
Eligibility
6 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 30, 2010 · Synced Sep 16, 2026, 9:10 AM EDT
Completed Phase 3 Interventional

Perennial Allergic Rhinitis Study In Pediatric Subjects

NCT00108914
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
GW685698X
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
2 Years to 12 Years
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
43
States / cities
Costa Mesa, California • Cudahy, California • Long Beach, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Sep 16, 2026, 9:10 AM EDT
Completed Phase 3 Interventional

To Assess the Safety of Ciclesonide, Applied as a Nasal Spray at Three Dose Levels, in the Treatment of Perennial Allergic Rhinitis in Pediatrics (BY9010/M1-405)

NCT00658918
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial, Hay Fever
Interventions
Ciclesonide nasal, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
2 Years to 5 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 1, 2016 · Synced Sep 16, 2026, 9:10 AM EDT
Completed Phase 3 Interventional

A Study of GW685698X for the Treatment Of Perennial Allergic Rhinitis in Adolescents and Adults

NCT00116818
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
GW685698X aqueous nasal spray
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Sep 16, 2026, 9:10 AM EDT
Completed Phase 4 Interventional Results available

Phase 4 Fluticasone Furoate Nasal Spray (VERAMYST) Long Term Pediatric Growth Study.

NCT00570492
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
Fluticasone furoate nasal spray, Placebo nasal spray
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 8 Years
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
50
States / cities
Oxford, Alabama • Little Rock, Arkansas • Huntington Beach, California + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Sep 16, 2026, 9:10 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Tolerability of a Nasal Spray to Treat Perennial Allergic Rhinitis

NCT00720382
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
0.15% azelastine hydrochloride, Mometasone furoate
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
703 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
59
States / cities
Oxford, Alabama • Fountain Valley, California • Huntington Beach, California + 50 more
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Sep 16, 2026, 9:10 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)

NCT06339008
View directory record Official record
Conditions
Perennial Allergic Rhinitis (PAR)
Interventions
LY3650150, Placebo, Standard therapy for INCS
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
26
States / cities
Huntington Beach, California • Inglewood, California • Laguna Niguel, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 16, 2026, 9:10 AM EDT
Completed Phase 3 Interventional Results available

Long Term Safety and Efficacy of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Perennial Allergic Rhinitis (PAR)

NCT02709538
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
GSP 301 NS, GSP 301 Placebo NS pH 3.7, GSP 301 Placebo NS pH 7.0
Drug
Lead sponsor
Glenmark Specialty S.A.
Industry
Eligibility
12 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
34
States / cities
Hot Springs, Arkansas • Encinitas, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Sep 16, 2026, 9:10 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effectiveness of Mometasone Nasal Irrigation for Chronic Rhinosinusitis

NCT03705793
View directory record Official record
Conditions
Chronic Rhinosinusitis (Diagnosis), Allergic Rhinosinusitis, Chronic Eosinophilic Rhinosinusitis
Interventions
Mometasone Furoate Nasal Irrigation, Mometasone Nasal Spray
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Sep 16, 2026, 9:10 AM EDT
Completed Phase 4 Interventional Results available

The Impact Of The Addition Of Budesonide To Low-Pressure, High-Volume Saline Sinus Irrigation For Chronic Rhinosinusitis

NCT02696850
View directory record Official record
Conditions
Rhinosinusitis, Chronic Eosinophilic Rhinosinusitis, Allergic Rhinosinusitis
Interventions
Budesonide, Saline alone
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 2, 2019 · Synced Sep 16, 2026, 9:10 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergies

NCT00712920
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
0.15% azelastine hydrochloride, 0.1% azelastine hydrochloride, Placebo
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
581 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
43
States / cities
Huntington Beach, California • Long Beach, California • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Sep 16, 2026, 9:10 AM EDT
Completed Phase 4 Interventional Results available

Nasacort AQ Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Children With Allergic Rhinitis

NCT01154153
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial and/or Seasonal
Interventions
Placebo nasal spray, Triamcinolone acetonide aqueous (TAA-AQ) nasal spray (NASACORT AQ), Claritin® Syrup
Drug
Lead sponsor
Sanofi
Industry
Eligibility
2 Years to 12 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
8
States / cities
Cypress, California • Stockbridge, Georgia • North Dartmouth, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2012 · Synced Sep 16, 2026, 9:10 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Biomarker-based Cockroach Sublingual Immunotherapy Study (BioCSI)

NCT00829985
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial, Asthma
Interventions
Glycerinated German Cockroach Allergenic Extract, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
4
States / cities
Denver, Colorado • Chicago, Illinois • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Sep 16, 2026, 9:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of House Dust Mite Allergen Challenge in Persons Using 1200 mg Gamma Tocopherol Supplements

NCT00466596
View directory record Official record
Conditions
Allergic Rhinitis, Mild Asthma
Interventions
Gamma Tocopherol
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 50 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 8, 2014 · Synced Sep 16, 2026, 9:10 AM EDT